This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox reserved 1169
From Proteopedia
(Difference between revisions)
| Line 6: | Line 6: | ||
A critical topic in the understanding of GPCRs is the transition from the inactive to active state. This transition is responsible for the [https://en.wikipedia.org/wiki/Signal_transduction transduction] of a signal from the extracellular to the intracellular space. The transition occurs when a ligand, NTS in the case of NTSR1, binds to the receptor causing a [https://en.wikipedia.org/wiki/Conformational_change conformational change] in the protein that leads to the activation of the intracellular G protein. Currently no crystal structures of the receptor in its unbound, inactive form exist making the transition more difficult to study. NTSR1 can be seen in <font color='#6495ED'>blue</font> and the ligand NTS can be seen in <font color='#32CD32'>green</font>.<ref name="White">PMID:23051748</ref> | A critical topic in the understanding of GPCRs is the transition from the inactive to active state. This transition is responsible for the [https://en.wikipedia.org/wiki/Signal_transduction transduction] of a signal from the extracellular to the intracellular space. The transition occurs when a ligand, NTS in the case of NTSR1, binds to the receptor causing a [https://en.wikipedia.org/wiki/Conformational_change conformational change] in the protein that leads to the activation of the intracellular G protein. Currently no crystal structures of the receptor in its unbound, inactive form exist making the transition more difficult to study. NTSR1 can be seen in <font color='#6495ED'>blue</font> and the ligand NTS can be seen in <font color='#32CD32'>green</font>.<ref name="White">PMID:23051748</ref> | ||
== Neurotensin == | == Neurotensin == | ||
| - | [https://en.wikipedia.org/wiki/Neurotensin Neurotensin (NTS)] is a 13-amino acid peptide originally isolated from [https://en.wikipedia.org/w/index.php?title=Bovinae&redirect=no bovine] [https://en.wikipedia.org/wiki/Hypothalamus hypothalamus]. NTS fulfills the roles of both a [https://en.wikipedia.org/wiki/Neurotransmitter neurotransmitter] and a [https://en.wikipedia.org/wiki/Neuromodulation neuromodulator] in the nervous system and a [https://en.wikipedia.org/wiki/Hormone hormone] in the periphery nervous system. NTS is a neuromodulator of dopamine transmission and of anterior [https://en.wikipedia.org/wiki/Pituitary_gland pituitary] hormone secretion. In the periphery of the digestive tract and cardiovascular system, NTS is a [https://en.wikipedia.org/w/index.php?title=Paracrine_signalling&redirect=no paracrine] and [https://en.wikipedia.org/wiki/Endocrine_system endocrine] modulator. Finally, NTS serves as a [https://en.wikipedia.org/wiki/Growth_factor growth factor] for many normal and cancerous cell types.<ref name="Vincent">PMID:10390649</ref> | + | [https://en.wikipedia.org/wiki/Neurotensin Neurotensin (NTS)] is a 13-amino acid peptide originally isolated from [https://en.wikipedia.org/w/index.php?title=Bovinae&redirect=no bovine] [https://en.wikipedia.org/wiki/Hypothalamus hypothalamus]. NTS fulfills the roles of both a [https://en.wikipedia.org/wiki/Neurotransmitter neurotransmitter] and a [https://en.wikipedia.org/wiki/Neuromodulation neuromodulator] in the nervous system and a [https://en.wikipedia.org/wiki/Hormone hormone] in the periphery nervous system. NTS is a neuromodulator of dopamine transmission and of anterior [https://en.wikipedia.org/wiki/Pituitary_gland pituitary] hormone secretion. In the periphery of the digestive tract and cardiovascular system, NTS is a [https://en.wikipedia.org/w/index.php?title=Paracrine_signalling&redirect=no paracrine] and [https://en.wikipedia.org/wiki/Endocrine_system endocrine] modulator. Finally, NTS serves as a [https://en.wikipedia.org/wiki/Growth_factor growth factor] for many normal and cancerous cell types. <ref name="Vincent">PMID:10390649</ref> |
| - | Only the C-terminal tail of NTS, amino acids 8-13, were resolved in the <scene name='72/721539/Nts8_13/2'>crystal structure</scene>.(PDB code:[http://www.rcsb.org/pdb/explore/explore.do?structureId=4GRV 4GRV)] | + | Only the C-terminal tail of NTS, amino acids 8-13, were resolved in the <scene name='72/721539/Nts8_13/2'>crystal structure</scene>.(PDB code:[http://www.rcsb.org/pdb/explore/explore.do?structureId=4GRV 4GRV)]The peptide is colored by element: <font color='#32CD32'>carbon</font>, <font color='#FF0000'>oxygen</font>, <font color='#0000CD'>nitrogen</font>. |
== Structure == | == Structure == | ||
=== Overall Structure === | === Overall Structure === | ||
Revision as of 22:04, 17 April 2016
Neurotensin Receptor (NTSR1)
References
- ↑ Millar RP, Newton CL. The year in G protein-coupled receptor research. Mol Endocrinol. 2010 Jan;24(1):261-74. Epub 2009 Dec 17. PMID:20019124 doi:10.1210/me.2009-0473
- ↑ Gui X, Carraway RE. Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats. Gastroenterology. 2001 Jan;120(1):151-60. PMID:11208724
- ↑ Selivonenko VG. [The interrelationship between electrolytes and phase analysis of systole in toxic goiter]. Probl Endokrinol (Mosk). 1975 Jan-Feb;21(1):19-23. PMID:1173461
- ↑ Fang Y, Lahiri J, Picard L. G protein-coupled receptor microarrays for drug discovery. Drug Discov Today. 2004 Dec 15;9(24 Suppl):S61-7. PMID:23573662
- ↑ 5.0 5.1 White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012 Oct 25;490(7421):508-13. doi: 10.1038/nature11558. Epub 2012 Oct 10. PMID:23051748 doi:http://dx.doi.org/10.1038/nature11558
- ↑ Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999 Jul;20(7):302-9. PMID:10390649
- ↑ 7.0 7.1 7.2 White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012 Oct 25;490(7421):508-13. doi: 10.1038/nature11558. Epub 2012 Oct 10. PMID:23051748 doi:http://dx.doi.org/10.1038/nature11558
- ↑ Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, Stevens RC. Allosteric sodium in class A GPCR signaling. Trends Biochem Sci. 2014 May;39(5):233-44. doi: 10.1016/j.tibs.2014.03.002. Epub , 2014 Apr 21. PMID:24767681 doi:http://dx.doi.org/10.1016/j.tibs.2014.03.002
- ↑ Valerie NC, Casarez EV, Dasilva JO, Dunlap-Brown ME, Parsons SJ, Amorino GP, Dziegielewski J. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Cancer Res. 2011 Nov 1;71(21):6817-26. doi: 10.1158/0008-5472.CAN-11-1646. Epub, 2011 Sep 8. PMID:21903767 doi:http://dx.doi.org/10.1158/0008-5472.CAN-11-1646
- ↑ Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009 Aug 15;69(16):6539-45. doi: 10.1158/0008-5472.CAN-09-0418. PMID:19679549 doi:http://dx.doi.org/10.1158/0008-5472.CAN-09-0418
